BACKGROUND: Beyond the hepatobiliary pathway, studies have demonstrated that direct transintestinal cholesterol efflux (TICE) of plasma-derived cholesterol may contribute to reverse cholesterol transport. The clinical evidence of TICE in human remains challenged because of the difficulty to discriminate the hepatobiliary and transintestinal routes in vivo.
Introduction
Until recently, the hepatobiliary pathway was described as the sole route involved in the fecal elimination of plasma cholesterol and reverse cholesterol transport (reviewed in [1] [2] [3] of a new pathway of cholesterol excretion named TICE for transintestinal cholesterol efflux. 4 Although molecular mechanisms remain largely unknown, several studies have contributed to a better understanding of this pathway. [4] [5] [6] [7] [8] [9] [10] [11] Although TICE appears to be twice more efficient than the biliary pathway to excrete plasma-derived cholesterol in mice, 6 the relative importance and more importantly the clinical relevance of TICE in human remains a crucial but open question. Several indirect evidences have nonetheless suggested the existence of TICE in human. 12, 13 In 1959, Cheng and Stanley first described an intestinal cholesterol secretion in three patients presenting a total obstruction of the biliary and pancreatic ducts. 12 Later, Simmonds et al performed intestine perfusions in humans and suggested that 44% of the cholesterol found in the intestinal lumen derived from intestinal cells. 13 The main criticism for these studies regarding the TICE existence is the lack of evidence that the cholesterol excreted in the intestinal lumen comes directly from the plasma. In 2013, we demonstrated with Ussing chambers that human jejunal biopsies actively excrete cholesterol from basolateral to luminal chambers, suggesting that TICE is operative and inducible in human. 8 Our proof-of-concept study aims to demonstrate by using cholesterol tracer that patients with a defective hepatobiliary pathway can excrete plasma-derived cholesterol in their feces.
Materials and methods

Clinical protocol
The « In vivo TICE » study was a single-center prospective interventional study and was conducted between 2014 and 2016 at the Digestive and Endocrine Surgery department of Nantes University Hospital and registered in clinicaltrials.gov as study NCT01958216. The goal of this proof of concept study was to provide the first proof of the TICE existence in humans by using stable isotopes in patients with bile duct diversion. The study was approved by the ethics committee (IRB/IEC) CPP Ouest IV (n 08/12) and the ANSM-French National Agency for Medicines and Health Products Safety (n 2012-A01666-35). The inclusion criteria were adult patients (aged $ 18 years) presenting a total obstruction of the intestinal biliary flow with an external biliary derivation. We excluded from the study patients with inflammatory bowel disease, aphagia, renal or hepatocellular insufficiency, primary intestinal tumor, cholangitis or severe sepsis, acute or chronic diarrhea, or under pregnancy. The biliary pathway obstruction was initially validated by magnetic resonance imaging before the setup of the external biliary cannulae. After signing the clinical consent, plasma, biliary, and fecal samples were harvested in patients at day 0. Then, bile diverted patients have received an intravenous injection of deuterated cholesterol diluted in intralipid 20%. The plasma, biliary, and fecal content of deuterated cholesterol will be measured, by mass spectrometry, at 24, 48, and 72 hours after the initial input.
Mass spectrometry measurement
The detailed protocols are available as Supplemental File.
Results
We recruited two patients with neoplasia of the root biliary duct (ie, cholangiocarcinomas). Their clinical characteristics are listed in Table 1 .
As a primary step, we verified and confirmed the complete obstruction of biliary pathways by bile-duct magnetic resonance imaging ( Fig. 1A ). Next, we confirmed by mass spectrometry analysis that lithocholic acid, the most abundant bile acid in the human feces, was undetectable in the feces of the two patients (data not shown). In addition, the use of a colorimetric enzymatic assay confirmed the absence of any bile acid species in the feces (data not shown). Together these results established that these two patients had a complete biliary duct obstruction, thereby ruling out the possibility for a biliary delivery of plasma-derived cholesterol in the gut.
After the setup of the external biliary drainage, we harvested blood, bile, and feces samples prior an intravenous injection of D7-cholesterol (100 mg) and 10 minutes, 24, 48, and 72 hours after the injection. We measured a significant amount of plasma D7cholesterol in both patients 10 minutes after injection ( Fig. 1B) with a subsequent reduction of D7-cholesterol levels during the three following days validating the efficiency of circulating cholesterol clearance pathways. We also quantified D7-cholesterol in the bile collected via the external cannula (Patient 1: 0.28, 0.29, and 0.76 mg, respectively, excreted during day 1, 2, and 3; Patient 2: 0.38, 1.37, and 0.43 mg, respectively, at day 1, 2, and 3).
Interestingly, despite a total obstruction of the biliary route, a significant amount of D7-cholesterol was detected in the feces of the two patients 48 and 72 hours after injection. Fecal D7-cholesterol was under the limit of detection in both patients 24 hours after the injection.
Regarding patient 1, we observed the appearance of the D7cholesterol peak at day 2 (Fig. 1C ) and quantified 0.13 mg of D7-cholesterol per gram of feces (Fig. 1B) . Patient 1 did not produce any feces at day 3. We observed a similar pattern with patient 2. Although, he did not produce feces at day 2, we quantified 0.33 mg of D7-cholesterol per gram of feces at day 3 ( Fig. 1B and C) .
Discussion
These data constituted the first direct proof that plasmaderived cholesterol can be excreted in the feces of patients with a complete biliary duct obstruction, thereby validating that TICE is operative in vivo in humans. By contrast with two previous studies, 12,13 the use of a cholesterol tracer allow us to specifically follow the fecal elimination of cholesterol from the plasma compartment. Interestingly, while we were completing this study, Groen's team published an in vivo cholesterol kinetic study performed in humans and showed by modeling cholesterol fluxes that TICE could contribute to 30%-35% of the cholesterol excreted in the feces under basal condition and can be strongly upregulated with ezetimibe. 9 Despite its novelty, some elements of our study can be opened for discussion. The design of the study focuses on few patients to provide a proof of concept evidence that plasma cholesterol can be eliminated in the feces of individuals with obstructed biliary pathway. Clearly, the very small sample size is a limitation, and additional experiments with more subjects are needed to precise the biliary and transintestinal flow measurement. Two independent pathways can contribute to the intestinal excretion of plasma cholesterol. TICE is an active pathway requiring several transporters both at the basolateral and apical sides of enterocytes (reviewed in 3, 14 ) . The rapid turnover of the epithelial intestinal cells can also contribute to a part of the clearance of the plasma-derived D7-cholesterol after its active uptake from the plasma. This phenomenon named shedding is difficult to quantify without intrusive methods that cannot be used in humans. In mouse models under unstimulated or stimulated conditions, shedding cells contribute from 10% to 30% of the cholesterol excreted in the feces. 4, 15 We cannot discard the possibility that a part of the fecal D7-cholesterol originates from desquamated cells, a phenomenon that we can call ''passive'' TICE.
For practical and logistical reasons but also because of the precarious health of our frail patients, we did not succeed to harvest their full feces production during the 3 days after injection. This would have been very helpful for estimating the relative importance of the hepatobiliary vs the transintestinal routes in plasma cholesterol elimination, as previously shown in mice and humans with mathematical models. 6, 9 However, if we assume that adult humans excrete about 200g of feces per day, we can extrapolate that at day 2, patient 1 excretes 297.5 mg of biliary D7-cholesterol and 26 mg of D7-cholesterol via the transintestinal route; at day 3, patient 2 excretes 432 mg of biliary D7-cholesterol and 66 mg of D7-cholesterol via TICE. Based on these calculations, TICE appears to be 6-to 10-fold less efficient than the hepatobiliary pathway to excrete plasma cholesterol. This low transintestinal efflux of plasma cholesterol can be explained, at least partly, by the complete obstruction/derivation of their biliary ducts. Indeed, hepatobiliary and transintestinal routes are two pathways that exist independently but TICE is strongly stimulated by cholesterol acceptors (phospholipids and bile acids) provided by the bile flow. 4, 5 Van der Velde et al reported that intestinal cholesterol excretion could occur in the absence of bile salts if luminal phospholipids are available. 4 We propose that the intestinal flow of D7-cholesterol excreted may be far from maximal in our patients because of the lack of bile acids as acceptors in the lumen and probably made possible by the luminal phospholipids provided by the diet.
To date, TICE remains a poorly characterized pathway and only few intestinal molecular players have been yet identified in mice as important for TICE regulation, among which apical transporters such as ABCG5/G8, 6 ABCB1, 8 and NPC1L1 9 and also the LDL receptor located at the basolateral side of enterocytes 8 (Fig. 2) . Interestingly, these molecular determinants have already been associated with cardiovascular diseases in several Mendelian randomization studies. [16] [17] [18] However, these transporters are not only located in intestinal cells but also in the liver, and thus the direct evidence that a defective TICE can promote cardiovascular disease progression remains to be established. An initial step was made when Ryan Temel et al provide the first evidence that TICE was an active component of the reverse cholesterol transport (RCT) pathway in mice. 7 The RCT route originally described by John Glomset in 1968, allows the efflux of cholesterol from peripheral cells to the HDL particles and its transport to the liver for fecal elimination (reviewed in [1] [2] [3] ). Because of its ability to reduce cholesterol content in macrophages located in the arterial walls, RCT has been considered for long time as an anti-atherogenic pathway (reviewed in [1] [2] [3] ). If TICE is an active and final component of the RCT, its stimulation should delay atherosclerosis progression. Generating specific pharmaceutical TICE modulators will be required to validate this hypothesis. Statins and ezetimibe are widely used in clinical practice to decrease plasma cholesterol by affecting cholesterol synthesis and intestinal cholesterol absorption. Interestingly, these drugs also stimulate TICE in vivo either in mice 8, 9 or in humans. 9 In addition, some preclinical data in mice suggest that FXR agonist (PX20606) can stimulate TICE, at least by increasing the hydrophilicity of the bile salt pool. 11 However, to the best of our knowledge, no drugs that specifically target TICE are currently in development but our data bring an additional but direct proof that TICE is an active pathway in humans and suggest that a better understanding of the molecular mechanisms behind this efflux could open new therapeutic options for patients at risk of cardiovascular diseases.
